European Life Sciences Symposium

Oksana is the Life Sciences Strategy and Solutions Lead at Amazon Web Services, where she drives global healthcare innovation. Her expertise centres on transforming commercial pharma operations and patient engagement through cutting-edge technologies. She specialises in helping life science companies build scalable solutions that harness Real-World-Data and GenAI to power advanced DTC/DTP models and intelligent patient support agents that improve treatment outcomes and support patient identification and diagnosis through personalized care.

David Duong, MD, MPH is the Director of Global Primary Health Care at the Harvard Medical School Center for Primary Care and in the Division of Global Health Equity at the Brigham and Women’s Hospital. David is responsible for the overall strategy development, partnership engagement, programmatic activities and donor relations for Global Primary Health Care in order to meet the goals and mission of Harvard Medical School as well as the local, national and global primary health care community. His work covers primary healthcare training, systems strengthening, co-design, policy and advocacy across Southeast Asia and in the United States. David has led many research studies and has published on health care systems, including co-leading the Lancet Global Health Commission on People-Centered Care for Universal Health Coverage. David is a primary care physician, a member of the World Health Organization's Technical Advisory Group on Integrated Clinical Care, and previously served on the World Economic Forum's Global Future Council on Health and Healthcare. He is also a former US Fulbright Scholar. David earned both his Bachelor’s Degree and Masters in Public Health, from the University of Michigan, a Medical Doctor from Harvard Medical School. He completed his internal medicine residency at the Brigham and Women’s Hospital.

Dr. Isabella Erb-Herrmann serves as a member of the Executive Board of AOK – Die Gesundheitskasse in Hessen, where she is responsible for health partner management, sickness benefit management, prevention, and long-term care insurance (“Soziale Pflegeversicherung”). Prior to joining AOK, she held several positions at international strategy consulting firms – most recently at The Boston Consulting Group – and at the pharmaceutical company UCB Pharma in Brussels. She is a trained business and production engineer from the ETH Zurich. Dr. Erb-Herrmann has extensive experience in both the German and international healthcare systems, from a consulting as well as a leadership perspective.

Amr is a courageous leader driven by creating positive impact for people, patients and the business. With close to 20 years of well-rounded industry experience, Amr brings solid leadership, sales, marketing, strategy, and new products commercialization experience, robust strategic and operational expertise across different global, regional and local roles, and 10 years of Oncology spanning across different stages of product lifecycle. In his most recent role as the VP, Global Head of Bavencio, Amr led the transformation of the brand both strategically and operationally, and delivered the highest sales and profit growth for Merck in 2023. Amr studied clinical pharmacy and business Administration, he has a global mindset, entrepreneurial spirit, and passion for innovation, science and business transformation.

Dr. Chrys Herrera is a seasoned pharmaceutical industry professional with over 15 years of experience in enhancing patient access to care. Currently serving as the Head of Health Equity and Access Realization at Merck Healthcare, he led the development of Merck's Health Equity framework to ensure equitable access to medicines. Chrys has been instrumental in expanding Merck's patient reach in low- and middle-income countries through cross-functional health system strengthening initiatives. Chrys has worked across multiple roles at Merck, where he designed and executed public-private partnerships, significantly enhancing the company's reputation and market growth in key therapeutic areas. Previously, he served as a consultant for the UPecon Health Policy Development Program, a USAID project focused on scaling up universal healthcare in the Philippines. Chrys is a physician with a background in development economics, and is dedicated to finding innovative ways of improving health systems.

Oliver is Vice President of GLP-1 Diabetes Global Commercial Strategy at Novo Nordisk. With over 20 years in the pharmaceutical industry, he has led the global brand Ozempic for the past four years, driving strategy and new indications in cardiovascular and chronic kidney disease. He’s passionate about advancing innovation that makes a real difference to people’s health and quality of life.

Innovation award winning pharma industry leader, founder, keynote and TEDx speaker, strategy expert with over 23 years in the NHS and industry (Roche, Amgen, ALMAC, ICON, Biogen, Novartis, and Novo Nordisk). Adama focuses on digital transformation with a passion for STEM, diversity, equity and inclusion. She has worked in multiple countries and in her spare time enjoys spending time with her daughter, the outdoors and fishing!

Dierk Neugebauer is a member of the Executive Board Bristol-Myers Squibb Germany and responsible for Market Access, Government Affairs, Commercial, Key Account Management, Hospital and Pricing. Mr. Neugebauer studied business administration and worked for the Health Insurance Barmer Ersatzkasse as a CEO from 1995 to 2007 for Bavaria, before he joined Fresenius Kabi Germany as a member of the Executive Management Board in 2007. From 2008 to 2011, he was Managing Director at Novartis Pharma GmbH Germany. Dierk Neugebauer was awarded with the Federal Cross of Merit on Ribbon in March 2024 and in April 2025 he has been appointed Honorary Consul of Lithuania in Nuremberg, Bavaria

Dr. Patel is a member of Houlihan Lokey’s Capital Markets Group, where he specialises in private capital markets transactions. He is responsible for delivering minority equity solutions, including growth capital and structured equity, for ambitious companies in a range of sectors. Dr. Patel has significant transactional experience in private capital markets, including fundraises for high- growth technology companies in Europe, Israel, and Asia. He has operated across a range of sectors, including healthcare & life sciences, climate tech, deep tech, software, and consumer. Prior to joining Houlihan Lokey, Dr. Patel was a Managing Director and Head of Growth Capital Solutions at Deutsche Numis, part of Deutsche Bank Group. Before that, he had roles as a venture capital and growth equity investor, including leading EMEA deals for Optum Ventures, the investment arm of UnitedHealth Group. Before becoming a financier, Dr. Patel was on the founding team of a digital health company that listed in New York. Dr. Patel has spent more than a decade as an operator, investor, and advisor to multiple high-growth companies. He began his career as an anaesthetics & intensive care doctor in London. Dr. Patel holds an MA and a BM BCh (Bachelor of Medicine, Bachelor of Surgery) from the University of Oxford.

Dr. Lars Henrik Peeck is currently Chief Business Development Officer at Astraveus, a company developing next‑generation cell therapy manufacturing platform called the Lakhesys Benchtop Cell Factory. His professional focus lies at the intersection of business development and bioprocess innovation. Prior to joining Astraveus, Dr. Peeck has held global leadership roles in R&D and business management in the life sciences sector of Merck KGaA for more than a decade. His track record includes: - Oversight of more than two dozen product launches in the pharmaceuticals manufacturing domain - Managing three technology acquisitions and post-acquisition integrations - Organizational leadership through innovation, business transformation, and growth initiatives In his current role, he is responsible for developing Astraveus' portfolio and commercialization strategy, expanding the company's reach in the CGT manufacturing ecosystem, and establishing strategic partnerships. Dr. Peeck holds a Ph.D. in Chemistry from Technische Universität Darmstadt (TUD).

Dr. Tra-Mi Phan is currently serving as Global Head of Medical Affairs at Nestlé Health Science, after an extensive experience in the Pharmaceutical and MedTech industries. With her strong foundation in medicine and strategy, she brings a multidimensional lens to the intersection of nutritional science, innovation and patient & consumer health.

John is a Managing Partner at Oliver Wyman and a member of the firm’s Global Leadership Team. He serves as CEO of the Oliver Wyman Forum, the firm’s platform for engaging leaders from across public and private sector on the issues shaping the future. John also founded and continues to lead Oliver Wyman’s Global Private Capital business. He works closely with clients at the intersection of capital, innovation and transformation. Prior to these roles, John served as Head of the Americas for Oliver Wyman and has over 30 years of consulting experience, advising the boards and senior executives of the world’s leading private and public sector organizations on strategy, organizational effectiveness, M&A and risk management. In addition to his leadership roles at Oliver Wyman, John is a board member of Safe Horizon (the largest victims’ services agency in the United States), Vice Chair of the Royal Academy of Dramatic Art (RADA), a member of the Young Presidents’ Organization, Wall Street Journal CEO Council and Advisory Board of Triple Private Equity. He also sits on the Investment Committees of Duke Capital and Asta Capital Partners.

Rob is a Principal at GHO Capital, having joined GHO in 2017. Rob currently spends time across pharma services and LST/Dx looking at investment opportunities across the US and Europe. He currently works closely with the management teams at Avid Bioservices, Validant and X-Chem. Prior to GHO, Rob worked in corporate finance and audit. He graduated from Manchester University with a first-class degree in Business Management and is a Chartered Accountant and CFA holder.

Dr Boris Stoffel is the Managing Director of Miltenyi Biotec B.V. & Co. KG and a member of the Executive Board. He also serves as a member of the Executive Board for BioRiver-Life Science im Rheinland e.V. and as the Chairman of both the Skulpturenpark Köln Foundation and the MESF Foundation. Previously, he founded and served as the CEO of MEMOREC Stoffel GmbH. He holds a PhD in Agricultural Engineering from TU Munich – Weihenstephan and completed postdoctoral research at the Institute for Medical Microbiology at the University of Cologne.

Alexandra Vallon-Eberhard is a seasoned innovation and business development leader with over 25 years of international experience spanning diagnostics, digital health, and life sciences. As Senior Director-CTO, Global Strategy & Partnering at Roche Diagnostics, she spearheads strategic partnerships and ecosystem development to advance patient-centric and solution-driven diagnostics fostering a holistic lifecare approach. Previously, Alexandra co-founded and led Signals Analytics from inception to acquisition, helping over 40 Fortune 500 companies shape their innovation and market strategies. She has also advised life sciences startups in their financial, strategic and operational growth through her role at Cukierman Investment House. She also has a strong background in immunology and virology, having earned her PhD at bioMérieux and conducted post-doctoral research at the Weizmann Institute of Science, for which she received 6 academic awards. Alexandra serves as Chairwoman of the Weizmann Young European Network, is a member of the Institute’s International Board, and sits on several advisory boards in digital health and longevity. She is a passionate advocate for transformative power of curiosity and collaboration as essential elements in creating meaningful solutions for humanity.

Holger Weintritt is Head of Product Supply for Bayer Pharmaceuticals. Holger has more than 20 years of industry experience in operations and supply chain. He started his career in the areas of process development, manufacturing, and general management. Afterwards, he held various positions with increasing responsibility in Supply Chain Management, both in Germany and the US. After having led global operations for API manufacturing, he assumed his current role as Head of Product Supply for the Bayer Pharmaceuticals division being responsible for global technical operations and supply chain. Holger Weintritt holds a PhD in organic chemistry from the Max Planck Institute in Muelheim an der Ruhr, Germany.